Tacrolimus - VIVUS

Drug Profile

Tacrolimus - VIVUS

Alternative Names: SPI-026

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Selten Pharma; Stanford University
  • Developer VIVUS
  • Class Lactones; Macrolides
  • Mechanism of Action Bone morphogenetic protein receptor type II modulators; Calcineurin inhibitors; Cytokine inhibitors; T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension

Most Recent Events

  • 06 Sep 2017 Tacrolimus - Selten Pharma receives Orphan Drug status for Pulmonary arterial hypertension in European Union
  • 09 Jan 2017 Tacrolimus licensed to VIVUS worldwide for the treatment of Pulmonary arterial hypertension
  • 09 Jan 2017 Selton assigns its license to patents owned by Stanford University and all rights to patent applications owned by Selten to VIVUS
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top